The Wall Street Journal’s Alicia Munday looks at the Pharmaceutical Industry’s position after the mid-term elections.  In a bit of a balancing act, the industry hopes to maintain the concessions that it won by partnering with the Democrats on recently passed health care bill.  But will also court the new GOP majority congress as it looks to capitalize on a more anti-regulatory sentiment among Republicans.

Read Entire Article